TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Wave Life Sciences
Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Wave Life Sciences reported significant Activin E reductions of up to 85% in its INLIGHT clinical trial for obesity treatment, with WVE-007 showing promising results in fat loss potential and safety profile across multiple dose cohorts.

Insights
JPMpJ   neutral

Maintains a steady portfolio position at 4.0% of assets


WVE   positive

Demonstrated dose-dependent Activin E reductions, positive safety profile, successful clinical trial progression, and promising potential for obesity treatment with WVE-007